-
Kenya's economy faces climate change risks: World Bank
-
Czechs wind up black coal mining in green energy switch
-
EU eyes migration clampdown with push on deportations, visas
-
Northern Mozambique: massive gas potential in an insurgency zone
-
Gold demand hits record high on Trump policy doubts: industry
-
UK drugs giant AstraZeneca announces $15 bn investment in China
-
Ghana moves to rewrite mining laws for bigger share of gold revenues
-
Russia's sanctioned oil firm Lukoil to sell foreign assets to Carlyle
-
Gold soars towards $5,600 as Trump rattles sabre over Iran
-
Deutsche Bank logs record profits, as new probe casts shadow
-
Vietnam and EU upgrade ties as EU chief visits Hanoi
-
Hongkongers snap up silver as gold becomes 'too expensive'
-
Gold soars past $5,500 as Trump sabre rattles over Iran
-
Samsung logs best-ever profit on AI chip demand
-
China's ambassador warns Australia on buyback of key port
-
As US tensions churn, new generation of protest singers meet the moment
-
Venezuelans eye economic revival with hoped-for oil resurgence
-
Samsung Electronics posts record profit on AI demand
-
Formerra to Supply Foster Medical Compounds in Europe
-
French Senate adopts bill to return colonial-era art
-
Tesla profits tumble on lower EV sales, AI spending surge
-
Meta shares jump on strong earnings report
-
Anti-immigration protesters force climbdown in Sundance documentary
-
Springsteen releases fiery ode to Minneapolis shooting victims
-
SpaceX eyes IPO timed to planet alignment and Musk birthday: report
-
Neil Young gifts music to Greenland residents for stress relief
-
Fear in Sicilian town as vast landslide risks widening
-
King Charles III warns world 'going backwards' in climate fight
-
Court orders Dutch to protect Caribbean island from climate change
-
Rules-based trade with US is 'over': Canada central bank head
-
Holocaust survivor urges German MPs to tackle resurgent antisemitism
-
'Extraordinary' trove of ancient species found in China quarry
-
Google unveils AI tool probing mysteries of human genome
-
UK proposes to let websites refuse Google AI search
-
Trump says 'time running out' as Iran threatens tough response
-
Germany cuts growth forecast as recovery slower than hoped
-
Amazon to cut 16,000 jobs worldwide
-
Greenland dispute is 'wake-up call' for Europe: Macron
-
Dollar halts descent, gold keeps climbing before Fed update
-
Sweden plans to ban mobile phones in schools
-
Deutsche Bank offices searched in money laundering probe
-
Susan Sarandon to be honoured at Spain's top film awards
-
Trump says 'time running out' as Iran rejects talks amid 'threats'
-
Spain eyes full service on train tragedy line in 10 days
-
Greenland dispute 'strategic wake-up call for all of Europe,' says Macron
-
SKorean chip giant SK hynix posts record operating profit for 2025
-
Greenland's elite dogsled unit patrols desolate, icy Arctic
-
Uganda's Quidditch players with global dreams
-
'Hard to survive': Kyiv's elderly shiver after Russian attacks on power and heat
-
Polish migrants return home to a changed country
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
X.Wong--CPN